KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to 12.83%.

  • Acadia Pharmaceuticals' EBITDA Margin rose 20.00% to 12.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.01%, marking a year-over-year increase of 1093.00%. This contributed to the annual value of 24.10% for FY2024, which is 3420.00% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' EBITDA Margin is 12.83%, which was up 4.87% from 12.24% recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year EBITDA Margin high stood at 59.13% for Q4 2024, and its period low was -97.88% during Q1 2022.
  • Moreover, its 3-year median value for EBITDA Margin was 12.24% (2025), whereas its average is 6.29%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 5,961bps in 2021, then slumped by 3,521bps in 2022.
  • Over the past 5 years, Acadia Pharmaceuticals' EBITDA Margin (Quarterly) stood at -34.15% in 2021, then soared by 40bps to -33.75% in 2022, then surged by 4,887bps to 15.12% in 2023, then skyrocketed by 4,401bps to 59.13% in 2024, then rose by 20bps to 12.83% in 2025.
  • Its last three reported values are 12.83% in Q3 2025, 12.24% for Q2 2025, and 7.90% during Q1 2025.